GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: LY-3819253 | LY-CoV555 | LY3819253
                                 Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Bamlanivimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
                                    
                                 | 
| Classification  | |
| Compound class | Antibody | 
| Withdrawn drug? | Yes | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 11876 | bamlanivimab | 
| Synonyms  | 
| LY-3819253 | LY-CoV555 | LY3819253 | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 1104 | 
| Other databases | |
| GtoPdb PubChem SID | 434321760 | 
| Search PubMed clinical trials | bamlanivimab | 
| Search PubMed titles | bamlanivimab | 
| Search PubMed titles/abstracts | bamlanivimab |